Paritaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise review

Código QR

Paritaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise review

Trana Hussaini1,2 1Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada; 2Pharmaceutical Sciences, Vancouver General Hospital, Vancouver, BC, Canada Abstract: The treatment for chronic hepatitis C has been revolutionized with the development of direct-acting ant...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Hussaini T
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Hepatitis C Paritaprevir Ombitasvir Dasabuvir 3D Regimen Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/5db086ab4bc344cea8a7abd9d0ae81d0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ombitasvir, paritaprevir, and ritonavir with peginterferon-α2a plus ribavirin in treatment-experienced patients with chronic hepatitis C virus genotype 1 infection
por: Bernstein D, et al.
Publicado: (2019)

Interrelationship of hepatitis C virus genotypes with patient characteristics in Bahrain
por: Abdulla MA, et al.
Publicado: (2017)

Hepatitis C in the Russian Federation: challenges and future directions
por: Mukomolov S, et al.
Publicado: (2016)

Expert opinion on the management of hepatitis C infection in Kuwait
por: Saad MF, et al.
Publicado: (2018)

Challenging hepatitis C-infected liver transplant patients
por: Oliver M, et al.
Publicado: (2016)

Hepatitis C in Lebanon: the burden of the disease and the value of comprehensive screening and treatment
por: Abou Rached A, et al.
Publicado: (2018)

Diagnosis and staging of fibrosis in patients with chronic hepatitis C: comparison and critical overview of current strategies
por: Mendes LC, et al.
Publicado: (2018)

Efficacy of Ombitasvir/Paritaprevir/Ritonavir plus Ribavirin in Treatment of Chronic Hepatitis C Patients with End Stage Renal Disease on Regular Hemodialysis
por: Naglaa El-Gendy, et al.
Publicado: (2020)

Hepatitis C infection in Egypt: prevalence, impact and management strategies
por: Gomaa A, et al.
Publicado: (2017)

Decreasing racial disparity with the combination of ledipasvir–sofosbuvir for the treatment of chronic hepatitis C
por: Naylor PH, et al.
Publicado: (2017)

Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life
por: Pol S, et al.
Publicado: (2016)

Hepatic sarcoidosis: Clinical characteristics and outcome
por: Christiana Graf, et al.
Publicado: (2021)

Rifaximin in the treatment of hepatic encephalopathy
por: Iadevaia MD, et al.
Publicado: (2011)

Epidemiology and treatment of autoimmune hepatitis
por: Francque S, et al.
Publicado: (2012)

Hepatitis C in Argentina: epidemiology and treatment
por: Gaite LA, et al.
Publicado: (2014)

Evolving concepts in the selection of immunosuppression regimen for liver transplant recipients
por: Locke JE, et al.
Publicado: (2011)

Transmission, diagnosis, and management of hepatitis E: an update
por: Mirazo S, et al.
Publicado: (2014)

Update on entecavir in the management of severe forms of Hepatitis B
por: Sacco R
Publicado: (2012)

Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies
por: Ismail MH, et al.
Publicado: (2011)

Ending hepatitis C in the United States: the role of screening
por: Coffin PO, et al.
Publicado: (2014)

Decline in HAV-associated fulminant hepatic failure and liver transplant in children in Argentina after the introduction of a universal hepatitis A vaccination program
por: Cervio G, et al.
Publicado: (2011)

The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia
por: Danish FA, et al.
Publicado: (2013)

Overt hepatic encephalopathy in Italy: clinical outcomes and healthcare costs
por: Roggeri DP, et al.
Publicado: (2015)

A high prevalence of extreme hyperferritinemia in acute hepatitis patients
por: Kazuhiro Kotoh, et al.
Publicado: (2009)

Antiviral therapy for chronic hepatitis B in the indeterminate phase is urgent
por: JIANG Jun
Publicado: (2021)

Novel drugs in the management of difficult-to-treat hepatitis C genotypes
por: Cartwright EJ, et al.
Publicado: (2013)

Interferon-free combination therapies for the treatment of hepatitis C: current insights
por: Holmes JA, et al.
Publicado: (2015)

Hepatitis C infection in Egypt: prevalence, impact and management strategies [Corrigendum]
por: Gomaa A, et al.
Publicado: (2017)

Percutaneous hepatic radiofrequency for hepatocellular carcinoma: results and outcome of 46 patients
por: Bertr, et al.
Publicado: (2015)

Risk Prediction of Nosocomial and Posthospital Discharge Infections in Alcohol‐Associated Hepatitis
por: Daniel D. Penrice, et al.
Publicado: (2021)

A case of hepatic portal venous gas due to viral gastroenteritis
por: Mirmanesh M, et al.
Publicado: (2013)

Efficacy of bowel preparation regimens for colon capsule endoscopy: a systematic review and meta-analysis
por: Thomas Bjoersum-Meyer, et al.
Publicado: (2021)

Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives
por: Degasperi E, et al.
Publicado: (2014)

Clinical features and prognosis of primary myelofibrosis with hepatic vascular disease and/or portal hypertension
por: WANG Jing
Publicado: (2021)

Patients in the indeterminate phase of chronic hepatitis B virus infection should be treated
por: JIANG Yingying
Publicado: (2021)

Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine
por: Lau T, et al.
Publicado: (2013)

Association between hepatic fat and subclinical vascular disease burden in the general population
por: Susanne Rospleszcz, et al.
Publicado: (2021)

Project ECHO Revisited: Propensity Score Analysis And HCV Treatment Outcomes
por: Page K, et al.
Publicado: (2019)

New-onset ascites as a manifestation of virologic relapse in patients with hepatitis C cirrhosis
por: Chua DL, et al.
Publicado: (2014)

Critical reappraisal of risk factors for occurrence of hepatocellular carcinoma in patients with hepatitis C virus
por: Bruno S, et al.
Publicado: (2011)